Co-Diagnostics Inc. (NASDAQ:CODX) said on Tuesday that it moved closer to launching its point-of-care tuberculosis testing technology in South Asia after its joint venture submitted a formal regulatory filing backed by strong clinical performance data. CoSara Diagnostics Pvt. Ltd., the company’s joint venture in India, filed an application with India’s Central Drugs Standard Control Organization seeking regulatory clearance for the CoSara PCR Mycobacterium tuberculosis test on the CoSara PCR Pro